The role of bile acids in functional GI disorders

Neurogastroenterology and Motility

Volumn 26, Issue 8, 2014, Pages 1057-1069

  Appleby, Richard N ^a   Walters, Julian R F ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Bile acid diarrhea; Bile acid malabsorption; Bile salts; Chronic functional constipation; Elobixibat; Enterohepatic circulation; Ileum; Obeticholic acid

Indexed keywords

6-ETHYLCHENODEOXYCHOLIC ACID; ANTIDIURETIC AGENT; BILE ACID; CHENODEOXYCHOLIC ACID; DIPEPTIDE; ELOBIXIBAT; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; THIAZEPINE DERIVATIVE;

ANALOGS AND DERIVATIVES; DIARRHEA; GASTROINTESTINAL DISEASES; HUMAN; IRRITABLE COLON; METABOLISM;

ANTIDIURETIC AGENTS; BILE ACIDS AND SALTS; CHENODEOXYCHOLIC ACID; DIARRHEA; DIPEPTIDES; FIBROBLAST GROWTH FACTORS; GASTROINTESTINAL DISEASES; HUMANS; IRRITABLE BOWEL SYNDROME; THIAZEPINES;

EID: 84904443299     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12370     Document Type: Review

References (124)

1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
2. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98.
3. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45(Suppl. 2): II37-42.
4. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther 2014; 39: 312-21.
5. Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 2009; 50(Suppl.): S120-5.
6. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res 2009; 50: 2340-57.
7. Brunner H, Northfield TC, Hofmann AF, Go VL, Summerskill WH. Gastric emptying and secretion of bile acids, cholesterol, and pancreatic enzymes during digestion. Duodenal perfusion studies in healthy subjects. Mayo Clin Proc 1974; 49: 851-60.
8. Ballatori N, Christian WV, Lee JY, Dawson PA, Soroka CJ, Boyer JL, Madejczyk MS, Li N. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005; 42: 1270-9.
9. Low-Beer TS, Pomare EW. Regulation of bile salt pool size in man. Br Med J 1973; 2: 338-40.
10. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241-59.
11. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999; 159: 2647-58.
12. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.
13. Zhang ZH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, Williamson C, Walters JRF. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol 2013; 304: G940-8.
14. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365-8.
15. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-25.
16. Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-6.
17. Triantis V, Saeland E, Bijl N, Oude-Elferink RP, Jansen PLM. Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19 - mediated down-regulation of cytochrome P450 7A1. Hepatology 2010; 52: 656-66.
18. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995; 81: 687-93.
19. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3: 543-53.
20. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005; 25: 2020-30.
21. Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11: 55-67.
22. Wallace K, Cowie DE, Konstantinou DK, Hill SJ, Tjelle TE, Axon A, Koruth M, White SA et al. The PXR is a drug target for chronic inflammatory liver disease. J Steroid Biochem Mol Biol 2010; 120: 137-48.
23. Schmidt DR, Holmstrom SR, Tacer KF, Bookout AL, Kliewer SA, Mangelsdorf DJ. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem 2010; 285: 14486-94.
24. Mroz MS, Keating N, Ward JB, Sarker R, Amu S, Aviello G, Donowitz M, Fallon PG et al. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut 2013; 63: 808-17.
25. Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, Li J, Iwahashi M et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 2007; 56: 2485-93.
26. Chiang PC, Thompson DC, Ghosh S, Heitmeier MR. A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys. J Pharm Sci 2011; 100: 4722-33.
27. Singh N, Yadav M, Singh AK, Kumar H, Dwivedi SK, Mishra JS, Gurjar A, Manhas A et al. Synthetic FXR agonist GW4064 is a modulator of multiple G-protein coupled receptors. Mol Endocrinol 2014; 28: 659-73.
28. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-91.
29. Kidd M, Modlin IM, Gustafsson BI, Drozdov I, Hauso O, Pfragner R. Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am J Physiol Gastrointest Liver Physiol 2008; 295: G260-72.
30. Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol 2002; 282: G443-9.
31. Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, Bunnett NW, Corvera CU. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 2013; 144: 145-54.
32. Poole DP, Godfrey C, Cattaruzza F, Cottrell GS, Kirkland JG, Pelayo JC, Bunnett NW, Corvera CU. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 2010; 22: 814-25.
33. Camilleri M, Vazquez-Roque MI, Carlson P, Burton D, Wong BS, Zinsmeister AR. Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neurogastroenterol Motil 2011; 23: 995-9, e458.
34. Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, Cevikbas F, Steinhoff M et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 2013; 123: 1513-30.
35. Duboc H, Tache Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis 2014; 46: 302-12.
36. Ichikawa R, Takayama T, Yoneno K, Kamada N, Kitazume MT, Higuchi H, Matsuoka K, Watanabe M et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology 2012; 136: 153-62.
37. Pols TW, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, Rizzo G, Gioiello A et al. TGR5 activation inhibits atherosclerosis by reducing macrophague inflammation and lipid loading. Cell Metab 2011; 14: 747-57.
38. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
39. Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012; 61: 1340-54.
40. Marshall RE, Anggiansah A, Owen WA, Owen WJ. The relationship between acid and bile reflux and symptoms in gastro-oesophageal reflux disease. Gut 1997; 40: 182-7.
41. Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98: 1940-4.
42. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-402.
43. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005; 50: 81-5.
44. Jenkins GJ, Harries K, Doak SH, Wilmes A, Griffiths AP, Baxter JN, Parry JM. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004; 25: 317-23.
45. McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther 2011; 34: 146-65.
46. Farre R. Pathophysiology of gastro-esophageal reflux disease: a role for mucosa integrity? Neurogastroenterol Motil 2013; 25: 783-99.
47. Fang D, Das KM, Cao W, Malhotra U, Triadafilopoulos G, Najarian RM et al. Barrett's esophagus: progression to adenocarcinoma and markers. Ann N Y Acad Sci 2011; 1232: 210-29.
48. Cipriani S, Mencarelli A, Bruno A, Renga B, Distrutti E, Santucci L, Baldelli F, Fiorucci S. Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. Br J Pharmacol 2013; 168: 225-37.
49. Nogi K, Haruma K, Taniguchi H, Yomota E, Okajima M, Hananoki M, Hata J, Kusunoki H et al. Duodenogastric reflux following cholecystectomy in the dog: role of antroduodenal motor function. Aliment Pharmacol Ther 2001; 15: 1233-8.
50. Atak I, Ozdil K, Yucel M, Caliskan M, Kilic A, Erdem H, Alimoglu O. The effect of laparoscopic cholecystectomy on the development of alkaline reflux gastritis and intestinal metaplasia. Hepatogastroenterology 2012; 59: 59-61.
51. Santarelli L, Gabrielli M, Candelli M, Cremonini F, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A. Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. Eur J Gastroenterol Hepatol 2003; 15: 975-9.
52. Vanheel H, Farre R. Changes in gastrointestinal tract function and structure in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 142-9.
53. Lamb K, Gebhart GF, Bielefeldt K. Luminal stimuli acutely sensitize visceromotor responses to distension of the rat stomach. Dig Dis Sci 2007; 52: 488-94.
54. Psichas A, Little T, Lal S, McLaughlin J. Colestyramine slows gastric emptying of liquids and reduces appetite in healthy subjects. Neurogastroenterol Motil 2012; 24: 1095-101.
55. Koop I, Schindler M, Bosshammer A, Scheibner J, Stange E, Koop H. Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids. Gut 1996; 39: 661-7.
56. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest 1971; 50: 1569-77.
57. Oddsson E, Rask-Madsen J, Krag E. Effect of glycochenodeoxycholic acid on unidirectional transepithelial fluxes of electrolytes in the perfused human ileum. Scand J Gastroenterol 1977; 12: 199-204.
58. Gordon SJ, Kinsey MD, Magen JS, Joseph RE, Kowlessar OD. Structure of bile acids associated with secretion in the rat cecum. Gastroenterology 1979; 77: 38-44.
59. Keely SJ, Scharl MM, Bertelsen LS, Hagey LR, Barrett KE, Hofmann AF. Bile acid-induced secretion in polarized monolayers of T84 colonic epithelial cells: structure-activity relationships. Am J Physiol Gastrointest Liver Physiol 2007; 292: G290-7.
60. Hofmann AF, Loening-Baucke V, Lavine JE, Hagey LR, Steinbach JH, Packard CA, Griffin TL, Chatfield DA. Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr 2008; 47: 598-606.
61. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, Lamsam J, Singh R et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010; 8: 159-65.
62. Sackmann M, Pauletzki J, Aydemir U, Holl J, Sauerbruch T, Hasford J, Paumgartner G. Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments: comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid. Hepatology 1991; 14: 1136-41.
63. Conley DR, Coyne MJ, Bonorris GC, Cheung A, Shoenfield LJ. Bile acid stimulation of colonic adenylate cyclase and secretion in the rabbit. Am J Dig Dis 1976; 21: 453-8.
64. Ao M, Sarathy J, Domingue J, Alrefai WA, Rao MC. Chenodeoxycholic acid stimulates Cl(-) secretion via cAMP signaling and increases cystic fibrosis transmembrane conductance regulator phosphorylation in T84 cells. Am J Physiol Cell Physiol 2013; 305: C447-56.
65. Alrefai WA, Saksena S, Tyagi S, Gill RK, Ramaswamy K, Dudeja PK. Taurodeoxycholate modulates apical Cl-/OH- exchange activity in Caco2 cells. Dig Dis Sci 2007; 52: 1270-8.
66. Camilleri M, Murphy R, Chadwick VS. Dose-related effects of chenodeoxycholic acid in the rabbit colon. Dig Dis Sci 1980; 25: 433-8.
67. Barcelo A, Claustre J, Toumi F, Burlet G, Chayvialle JA, Cuber JC, Plaisancie P. Effect of bile salts on colonic mucus secretion in isolated vascularly perfused rat colon. Dig Dis Sci 2001; 46: 1223-31.
68. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-77.
69. Raufman JP, Zimniak P, Bartoszko-Malik A. Lithocholyltaurine interacts with cholinergic receptors on dispersed chief cells from guinea pig stomach. Am J Physiol 1998; 274: G997-1004.
70. Bajor A, Gillberg P-G, Abrahamsson H. Bile acids: short and long term effects in the intestine. Scand J Gastroenterol 2010; 45: 654-64.
71. Sun Y, Fihn BM, Sjovall H, Jodal M. Enteric neurones modulate the colonic permeability response to luminal bile acids in rat colon in vivo. Gut 2004; 53: 362-7.
72. Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE 2011; 6: e25637.
73. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 2009; 183: 6251-61.
74. Chen X, Yang D, Shen W, Dong HF, Wang JM, Oppenheim JJ, Howard OMZ et al. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm Res 2000; 49: 744-55.
75. Cheng K, Raufman JP. Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. Biochem Pharmacol 2005; 70: 1035-47.
76. Hylemon PB, Zhou H, Pandak WM, Ren G, Dent P. Bile acids as regulatory molecules. J Lipid Res 2009; 50: 1509-20.
77. Yui S, Kanamoto R, Saeki T. Biphasic regulation of cell death and survival by hydrophobic bile acids in HCT116 cells. Nutr Cancer 2009; 61: 374-80.
78. Bernstein C, Bernstein H, Garewal H, Dinning P, Jabi R, Sampliner RE, McCuskey MK, Panda M et al. A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. Cancer Res 1999; 59: 2353-7.
79. Payne CM, Crowley-Skillicorn C, Bernstein C, Holubec H, Moyer MP, Bernstein H. Hydrophobic bile acid-induced micronuclei formation, mitotic perturbations, and decreases in spindle checkpoint proteins: relevance to genomic instability in colon carcinogenesis. Nutr Cancer 2010; 62: 825-40.
80. Shin A, Camilleri M, Vijayvargiya P, Busciglio I, Burton D, Ryks M, Rhoten D, Lueke A et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 1270-5 e1.
81. Abrahamsson H, Ostlund-Lindqvist A-M, Nilsson R, Simren M, Gillberg P-G. Altered bile acid metabolism in patients with constipation-predominat irritable bowel syndrome and functional constipation. Scand J Gastroenterol 2008; 43: 1483-8.
82. Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, Burton D, Carlson P et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139: 1549-58, 58 e1.
83. Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 2011; 106: 2154-64.
84. Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011; 106: 1803-12.
85. Hofmann AF. The syndrome of ileal disease and the broken enterohepatic circulation: cholerhetic enteropathy. Gastroenterology 1967; 52: 752-7.
86. Thaysen EH, Pedersen L. Idiopathic bile acid catharsis. Gut 1976; 17: 965-70.
87. Vijayvargiya P, Camilleri M, Shin A, Saenger A. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013; 11: 1232-9.
88. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707-17.
89. Sciarretta G, Vicini G, Fagioli G, Verri A, Ginevra A, Malaguti P. Use of 23-selena-25-homocholyltaurine to detect bile acid malabsorption in patients with illeal dysfunction or diarrhea. Gastroenterology 1986; 91: 1-9.
90. Sciarretta G, Fagioli G, Furno A, Vicini G, Cecchetti L, Grigolo B, Verri A, Malaguti P. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut 1987; 28: 970-5.
91. Bajor A, Tornblom H, Rudling M, Ung KA, Simren M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2014.
92. Pattni SS, Brydon WG, Dew T, Johnston IM, Nolan JD, Srinivas M, Basumani P, Bardhan KD et al. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharmacol Ther 2013; 38: 967-76.
93. Eusufzai S, Axelson M, Angelin B, Einarsson K. Serum 7 alpha-hydroxy-4-cholesten-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test. Gut 1993; 34: 698-701.
94. Sauter GH, Munzing W, von Ritter C, Paumgartner G. Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum. Dig Dis Sci 1999; 44: 14-9.
95. Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 2005; 129: 1445-53.
96. Camilleri M, Nadeau A, Tremaine WJ, Lamsam J, Burton D, Odunsi S, Sweetser S, Singh R. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil 2009; 21: 734-e43.
97. Covington JA, Westenbrink EW, Ouaret N, Harbord R, Bailey C, O'Connell N, Cullis J, Williams N et al. Application of a novel tool for diagnosing bile acid diarrhoea. Sensors 2013; 13: 11899-912.
98. van Tilburg AJ, de Rooij FW, van den Berg JW, van Blankenstein M. Primary bile acid diarrhoea without an ileal carrier defect: quantification of active bile acid transport across the ileal brush border membrane. Gut 1991; 32: 500-3.
99. Bajor A, Kilander A, Fae A, Galman C, Jonsson O, Ohman L, Rudling M, Sjovall H et al. Normal or increased bile acid uptake in isolated mucosa from patients with bile acid malabsorption. Eur J Gastroenterol Hepatol 2006; 18: 397-403.
100. Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest 1997; 99: 1880-7.
101. Montagnani M, Love MW, Rossel P, Dawson PA, Qvist P. Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand J Gastroenterol 2001; 36: 1077-80.
102. Balesaria S, Pell RJ, Abbott LJ, Tasleem A, Chavele K-M, Barley NF, Khair U, Simon A et al. Exploring possible mechanisms for primary bile acid malabsorption: evidence for different regulation of ileal bile acid transporter transcripts in chronic diarrhoea. Eur J Gastroenterol Hepatol 2008; 20: 413-22.
103. Walters JRF, Tasleem AM, Omer OS, Brydon WG, Dew T, Roux CWL. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009; 7: 1189-94.
104. van Tilburg AJ, de Rooij FW, van den Berg JW, van Blankenstein M. Primary bile acid malabsorption: a pathophysiologic and clinical entity? Scand J Gastroenterol Suppl 1992; 194: 66-70.
105. Pattni SS, Brydon WG, Dew T, Walters JR. Fibroblast growth factor 19 and 7alpha-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea. Clin Transl Gastroenterol 2012; 3: e18.
106. Wong BS, Camilleri M, Carlson PJ, Guicciardi ME, Burton D, McKinzie S, Rao AS, Zinsmeister AR et al. A Klothobeta variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 2011; 140: 1934-42.
107. Wong BS, Camilleri M, Carlson P, McKinzie S, Busciglio I, Bondar O, Dyer RB, Lamsam J et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012; 10: 1009-15 e3.
108. Wong BS, Camilleri M, Carlson PJ, Odunsi-Shiyanbade S, McKinzie S, Busciglio I, Burton D, Zinsmeister AR. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci 2012; 57: 1222-6.
109. Camilleri M, Klee EW, Shin A, Carlson P, Li Y, Grover M, Zinsmeister AR. Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit. Am J Physiol Gastrointest Liver Physiol 2014; 306: G13-26.
110. Johnston IM, Pattni SS, Lin J, Nolan JD, Dew T, Walters JRF. Meal-stimulated FGF19 response and genetic polymorphisms in Primary Bile Acid Diarrhea. Gastroenterology 2012; 142: S268.
111. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741-7.
112. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012; 26: 312-24.
113. Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 513-20, e246-7.
114. Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, Angelin B, Hyotylainen T et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17: 225-35.
115. Hofmann AF, Poley JR. Cholestyramine treatment of diarrhea associated with ileal resection. N Engl J Med 1969; 281: 397-402.
116. Stotzer P-O, Abrahamsson H, Bajor A, Sadik R. Effect of cholestyramine on gastrointestinal transit in patients with idiopathic bile acid diarrhea: a prospective, open-label study. Neuroenterology 2013; 2.
117. Borghede MK, Schlutter JM, Agnholt JS, Christensen LA, Gormsen LC, Dahlerup JF. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ((75)SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea. Eur J Intern Med 2011; 22: e137-40.
118. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007; 99: 530-4.
119. Jacobsen O, Hojgaard L, Moller EH, Weilandt TO, Thale M, Jarnum S, Krag E. Effect of enterocoated cholestyramine on bowel habit after ileal resection: a double blind crossover study. Br Med J 1985; 290: 1315-8.
120. Walker JR, Brown K, Rohatagi S, Bathala MS, Xu C, Wickremasingha PK, Salazar DE, Mager DE. Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol). J Clin Pharmacol 2009; 49: 1185-95.
121. Wedlake L, Thomas K, Lalji A, Anagnostopoulos C, Andreyev HJ. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin Ther 2009; 31: 2549-58.
122. Johnston IM, Nolan JD, Dew T, Shapiro D, Walters JRF. A new therapy for chronic diarrhea? A proof of concept study of the FXR agonist obeticholic acid in patients with primary bile acid diarrhea. Dig Dis Week Orlando FL 2013; 144: s-60.
123. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-82 e1.
124. Bajor A, Kilander A, Galman C, Rudling M, Ung KA. Budesonide treatment is associated with increased bile acid absorption in collagenous colitis. Aliment Pharmacol Ther 2006; 24: 1643-9.